TD Asset Management Inc Acquires 47,051 Shares of Edwards Lifesciences Corporation $EW

TD Asset Management Inc increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.4% during the 4th quarter, HoldingsChannel reports. The firm owned 778,129 shares of the medical research company’s stock after buying an additional 47,051 shares during the period. TD Asset Management Inc’s holdings in Edwards Lifesciences were worth $66,335,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Washington Trust Advisors Inc. boosted its stake in Edwards Lifesciences by 15.6% during the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after purchasing an additional 17,625 shares during the period. Azzad Asset Management Inc. ADV boosted its stake in Edwards Lifesciences by 330.5% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock valued at $1,651,000 after purchasing an additional 16,296 shares during the period. Elo Mutual Pension Insurance Co boosted its stake in Edwards Lifesciences by 39.9% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after purchasing an additional 25,562 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in shares of Edwards Lifesciences by 57.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 37,880 shares of the medical research company’s stock worth $2,946,000 after acquiring an additional 13,820 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after acquiring an additional 23,514 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 1.6%

NYSE EW opened at $86.02 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company’s 50 day simple moving average is $82.22 and its 200 day simple moving average is $83.07. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $89.48. The company has a market capitalization of $49.53 billion, a P/E ratio of 45.75, a PEG ratio of 2.19 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 95,057 shares of company stock valued at $7,874,217 over the last quarter. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on EW. Robert W. Baird upped their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. BTIG Research upped their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.